Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase II, 2nd Line Melanoma - RAND Monotherapy

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: January 30, 2008
Last updated: September 23, 2015
Last verified: September 2015
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks

Condition Intervention Phase
Drug: Anti-CD137 (4-1BB) (BMS-663513)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate [ Time Frame: every 6 weeks starting at week 12 after randomization ]

Secondary Outcome Measures:
  • Safety profiles [ Time Frame: throughout the study ]
  • Disease response rate [ Time Frame: end of study ]
  • Disease control rate [ Time Frame: end of study ]
  • 1-year survival [ Time Frame: end of study ]
  • Pharmacokinetics [ Time Frame: throughout the study ]
  • Pharmacodynamics [ Time Frame: throughout the study ]
  • Biomarkers [ Time Frame: throughout the study ]

Enrollment: 158
Study Start Date: March 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
0.1 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 2
1 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 3
1 mg/kg every 6 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 4
5 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvant and/or neoadjuvant therapy, the subject must have documented disease progression from the last treatment and also received one additional line of systemic therapy for metastatic disease.
  • Men and women, who are at least 18 years of age

Exclusion Criteria:

  • Ocular or mucosal melanoma
  • Complete surgical resection of all identifiable sites of disease
  • Symptomatic brain metastasis. Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by computerized axial tomography (CT) scan or magnetic resonance imaging (MRI). Subjects with stable brain metastasis and those who were previously treated with radiotherapy or surgery must have no current evidence of symptomatic brain metastasis and are off steroid therapy for at least 4 weeks prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00612664

  Show 32 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT00612664     History of Changes
Other Study ID Numbers: CA186-006
Study First Received: January 30, 2008
Last Updated: September 23, 2015

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 24, 2017